Poor
Non-Aligned
Patient Risk:
Moderate
Summary
Category Scores
Accurate Statements
Taking Benadryl (diphenhydramine) with Lipitor can lead to reduced efficacy of Lipitor.
Not supported by the provided Lipitor label excerpts.
Unsupported Statements
Benadryl (diphenhydramine) has anticholinergic properties.
The provided Lipitor prescribing information excerpts do not discuss diphenhydramine/anticholinergic properties.
Anticholinergic medications, like Benadryl, can alter the absorption of Lipitor (atorvastatin).
No support in the provided Lipitor drug interaction excerpts.
Diphenhydramine reduced the bioavailability of atorvastatin by approximately 20%.
The provided Lipitor excerpts do not contain any diphenhydramine-specific pharmacokinetic/bioavailability data or a 20% reduction figure.
The anticholinergic properties of Benadryl may decrease the amount of Lipitor absorbed into the bloodstream, making it less effective at lowering cholesterol levels.
Not supported by the provided Lipitor label excerpts (no discussion of diphenhydramine/anticholinergic effect on absorption or cholesterol-lowering efficacy).
Avoid taking Lipitor within a few hours of taking Benadryl or any other anticholinergic medication.
The provided Lipitor interaction excerpts list specific interaction categories (e.g., strong CYP3A4 inhibitors, fibrates, niacin, cyclosporine, and grapefruit juice) and do not provide timing guidance with anticholinergic medications or diphenhydramine.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Any label-supported interaction information relevant to diphenhydramine/anticholinergics (e.g., whether such agents are discussed and whether any dosing interval is recommended).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The interaction claims include specific quantitative PK effects and a dosing-interval recommendation that are not supported by the provided Lipitor label excerpts; this could lead to unnecessary or incorrect avoidance timing relative to Lipitor dosing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Non-Aligned
Primary Issue
Unsupported diphenhydramine/anticholinergic interaction claims (including ~20% bioavailability reduction) and unsupported timing advice to avoid concomitant dosing within a few hours.
Suggested Improvement
Limit interaction statements to those supported by the provided Lipitor label excerpts (e.g., CYP3A4 inhibitors, cyclosporine, fibrates, niacin/lipid-modifying doses, and grapefruit juice) and remove quantitative PK and anticholinergic timing guidance unless explicitly present in the prescribing information.